Suchergebnisse - "Faia, Kerrie"

PubPharm (21)

1

Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study

enthalten in: American journal of hematology | 2018

von O'Brien, S. | Patel, M. | Kahl, B. | +14

2

METHODS AND COMPOSITIONS FOR IDENTIFICATION, ASSESSMENT AND TREATMENT OF CANCERS ASSOCIATED WITH HEDGEHOG SIGNALING

enthalten in: Europäisches Patentamt | 2018

von MACDOUGALL JOHN R | PAEZ JUAN GUILLERMO | MCGOVERN KAREN J | +6

3

The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies

enthalten in: PloS one | 2018

von Faia, K. | White, K. | Murphy, E. | +5

4

Abstract 376: Combination of duvelisib with either ibrutinib or dexamethasone prevents mTOR-dependent feedback in aggressive B-cell lymphoma cell lines

enthalten in: Cancer research | 2016

von White, K. | Murphy, E. | Faia, K. | +6

5

Impact of the Smoothened inhibitor, IPI-926, on smoothened ciliary localization and Hedgehog pathway activity

enthalten in: PloS one | 2014

von Peluso, M. | Campbell, V. | Harari, J. | +9

6

PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models

enthalten in: Chemistry & biology | 2013

von Winkler, D. | Faia, K. | DiNitto, J. | +24

CommentIn: Chem Biol. 2013 Nov 21;20(11):1309-10. - PMID 24267274

7

PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models

enthalten in: Chemistry & biology | 2013

von Winkler, D. | Faia, K. | DiNitto, J. | +24

8

The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway

enthalten in: Xenobiotica; the fate of foreign compounds in biological systems | 2013

von Smith, S. | Hoyt, J. | Whitebread, N. | +23

9

The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway

enthalten in: Xenobiotica | 2013

von Smith, S. | Hoyt, J. | Whitebread, N. | +23

10

Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2013

von Jimeno, A. | Weiss, G. | Miller, W. | +13